| Literature DB >> 26315652 |
Abstract
In order to assure the quality and safety of future advanced cell therapies it is vital to ensure that source materials including the donor cells have been assessed and demonstrated as suitable for use in the development and manufacture of such new medicines. Here we provide a brief overview of the key issues in the delivery of quality controlled and safety tested seed stocks of human pluripotent stem cell lines to support stem cell research and the development of advanced cell therapies. We also reflect on the importance of national and internationally coordinated cell banking systems in this process in order to promote more efficient development of cell therapies.Entities:
Keywords: Bio-banking; Cell therapy; Quality control; Regenerative medicines; hESC; iPSC
Mesh:
Year: 2015 PMID: 26315652 DOI: 10.1016/j.biologicals.2015.07.007
Source DB: PubMed Journal: Biologicals ISSN: 1045-1056 Impact factor: 1.856